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Abstract Invasive fungal disease (IFD) is an important infec-
tion with high rates of morbidity and mortality in hospitalized
patients. Data on incidence, risk factors, and mortality of IFD
in the pediatric population, mainly in South America, are
scarce. The aim of this paper was to review the literature about
the most important IFD in pediatrics in South America. We
searched three electronic databases (Medline, Lilacs, and
Cochrane databases) for studies published between 2012 and
2015; case reports and editorial were excluded. Twenty-two
articles were found on Candida spp. infections; eight on
Paracoccidiodes spp.; two on Cryptococcus spp.; and one
on Aspergillus spp. Candida albicans was the main agent,
followed by Candida parapsilosis in pediatric population.
Paracoccidioides spp. had a prevalence ranging from 2.3 to
35.3 % with ages between 11 and 29 years, malnutrition, and
hepatic involvement related to the worst prognosis.
Cryptococcus spp. showed a prevalence of 2.6 % in under
16 years old, with cryptococcal meningitis most observed,
mainly by Cryptococcus neoformans (94.1 %). Aspergillosis
and other mold infections, as zygomycosis and fusariosis
occurring mostly in immunocompromised children, related
with relevant morbidity and mortality in this population.
Keywords Mycoses . Children . South America . Fungal
infection . Pediatric fungal infections
Introduction
Invasive fungal disease (IFD) is a relatively common and po-
tentially lethal infection in hospitalized children, especially in
patients with serious underlying diseases such as hematolog-
ical malignancies or critically ill patients hospitalized in inten-
sive care units (ICUs), that prolong hospital stay, have elevat-
ed morbidity and mortality rates, and increase medical care
costs. Multiple surveillance networks have documented a high
incidence of pediatric fungal bloodstream infections [1] espe-
cially in susceptible hosts [2, 3]. IFD are the leading infectious
cause of death in children with cancer or following an organ or
hematopoietic stem cell transplant (HSCT) [4, 5]. The case
fatality rate associated with pediatric fungal sepsis is 13 %,
the second highest rate of all causes of sepsis in children in
USA [6].
Studies describing the epidemiology, clinical and laborato-
ry characteristics of IFD have been performed mostly in adult
populations [7]. There are some differences in risk factors and
features for IFD between adults and children, and the use of
adult data to manage these infections in pediatric setting may
be inappropriate. Apart from this, the incidence and epidemi-
ology of IFD may differ significantly depending on the geo-
graphic region [8]. Data on incidence, risk factors, and mor-
tality of IFD in the pediatric population in South America are
scarce. The knowledge of these epidemiological differences to
implement appropriate strategies of prevention, diagnosis, and
therapy is noteworthy. The aim of this paper is to review the
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literature about the most important IFD in pediatrics in South
America.
Methods
Three electronic databases were searched (Medline, Lilacs,
and Cochrane databases) for studies published between 2012
and 2015 with the following MeSH terms: invasive mycoses,
mycoses, invasive fungal infection, yeast infection, mold in-
fection, Candida infection, pediatric fungal infections, chil-
dren, America, and South America. There were no language
restrictions for these searches.
For inclusion, the studies had to have results of IFD in
pediatric patients (0 to 18 years old) from South America.
Case reports and editorials were excluded (Fig. 1).
Of the studies identified in the updated review, 22 were on
Candida spp. infections [8–29] (five articles only in neonatal
patients), 8 on Paracoccidiodes spp. [30–37], 2 about
Cryptococcus spp. [38, 39], and 1 on Aspergillus spp. [40].
The other selected studies were about the following topics: one
epidemiological descriptive study [41], one identified risk factors
associated with IFD in patients with cancer [42], one about pro-
phylaxis [43], and one related with the environment as a source
of mold infections in pediatric patients with cancer [44].
Main studies included in this revision are shown in Table 1
(candidiasis, paracoccidiodomicosis, cryptoccocosis, aspergil-
losis, and others)
Candida spp.
Candida spp. is a commensal microorganism that naturally
inhabits various sites in the human body (including the
gastrointestinal and respiratory tracts) and in part of the vag-
inal and urethral microbiota. These microorganisms can be-
come pathogenic as a result of alterations in host defense
mechanisms or breakdown of anatomical barriers—situations
that are common in hospitalized patients who receive antibi-
otics or undergo frequent invasive procedures. Candidemia
often occurs in patients admitted to neonatal or surgical ICUs
[46].
Candida species are the third most common cause of pedi-
atric health care-associated bloodstream infection in the USA
and Europe. The attributable mortality from invasive candidi-
asis in children is 10 %, and invasive candidiasis is associated
with prolonged hospital stay and increased costs [47]. Inap-
propriate antifungal therapy and the occurrence of infections
by resistant species can impact mortality rate.
The epidemiology of such infections varies among differ-
ent geographic regions and even between medical centers
within the same region with temporal variability [48–51].
The Global Antifungal Surveillance Program, ARTEMIS
DISK, analyzed a total of 256,882 Candida isolates obtained
from 142 medical centers in Asia, Latin America, Europe,
Africa, and North America between 1997 and 2007, showing
that the most common species globally was Candida albicans
(65.3 %), followed by Candida glabrata (11.3 %), Candida
tropicalis (7.2), Candida parapsilosis (6.0 %), and Candida
krusei (2.4 %). These five Candida spp. are important world-
wide, but their frequency varied significantly according to the
setting [50, 51].
Little is known about the epidemiology of candidemia in
South America, especially in pediatric patients. Currently,
there are 22 studies about this infection which include children
[8–29]. From these, only three included exclusively pediatric
patients [14, 22, 26] and from these two followed patients with
candidemia [22, 26] and only one analyzed samples of C.
parapsilosis from blood [14], 11 studies included adult and
pediatric patients [8, 10–13, 15, 16, 18, 23, 24, 27], 5 studied
included only neonates [19–21, 28, 29], 3 were articles about
review [25] and recommendations [21, 28], 1 did not informed
the age of the patients [16], and 1 was on samples collected
from health professionals and the environment [9]
(Appendix 1).
C. albicans was reported as the most common species
causing candidemia an epidemiological shift toward non-
albicans [51]. In Brazil and some other countries in Latin
America, C. parapsilosis is responsible for 20–30 % of noso-
comial candidemias in general population [52].
Analyzing the two studies performed in Latin America
(LA) which enrolled only pediatric patients, the first was a
prospective, multicenter study of active surveillance
candidemia in seven countries in LA. This study enrolled
302 patients under 18 years, 89 neonates and 213 children
during a 2-year period. Non-albicans Candida species pre-
dominated in neonates and children; C. albicans alone was
1254 articles identified 
1191 articles excluded 
63 potentially relevant articles 
identified
26 articles excluded 
37 articles included 
Fig. 1 Flow diagram for invasive fungal disease in South America
update review
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the main specie (43.8 % neonates and 35.7 % children),
followed by C. parapsilosis (27 % neonates and 26.3 % chil-
dren) [8]. Comparing this study with the other largest study
published in 2012 by the International Pediatric Fungal Net-
work, which enrolled 221 pediatric patients with invasive can-
didiasis (25 neonates and 196 children) in the USA, Europe,
and Asia over a 5-year period from 2007 to 2011 [53], the two
main epidemiological differences are the high frequency of C.
tropicalis and the low frequency of C. glabrata in LA.
Another study from LA, performed in Brazil, analyzed the
frequency of yeasts of the genus Candida over a 4-year peri-
od, isolated from 104 patients from 5 to 11 years of age,
admitted to a public hospital of the city of Sao Paulo, Brazil.
In this study, non-albicans species predominated (63.5 %) and
C. tropicalis was slightly more frequent than C. parapsilosis
(24.03 and 22.11 %, respectively). On the contrary in LA
study, C. parapsilosis was more frequent than C. tropicalis
(26.3 vs 14.6 %) [26].
This high prevalence ofC. parapsilosis in pediatric patients
could be explained by the fact that this species is related to
prematurity, presence of central venous catheters, use of total
parenteral nutrition [53], and the use of mechanical ventilation
[11]. The high prevalence of C. parapsilosis and C. tropicalis
as etiologic agents of candidemia in LA has been recorded in
other studies which include children and adults [52, 54].
Candidemia by C. tropicalis related with a worse prognosis
compared with candidemia by other species in neutropenic
patients [11].
Anatomical and physiological differences between the pe-
diatric and adult patients change the susceptibility to infec-
tions caused by different species of Candida, which therefore
influences the antifungal treatment approach, including issues
related to the toxicity of the drugs, pharmacokinetic, and dos-
age [55]. Data regarding the pattern of resistance of etiologic
agents is a powerful tool to guide prophylactic, preemptive,
and empiric antifungal therapy [56, 57]. Bonfietti et al. in
2012 evaluated the incidence and susceptibility profile of
Candida spp. causative agents of bloodstream infections in a
Brazilian tertiary care hospital. They found that C. albicans,
C. parapsilosis, and C. tropicalis isolates presented high sus-
ceptibility to all antifungal agents tested. The highest flucon-
azole MICs were observed for C. parapsilosis isolates from
two patients who were successfully treated with amphotericin
B or fluconazole monotherapy [11]. Recommendation for an-
tifungal therapy in neonates and children with IC in LA is
described in Table 2.
Paracoccidioidomycosis
Paracoccidioidomycosis (PCM) is a systemic infection caused
by the dimorphic species of fungus Paracoccidioides
brasiliensis or Paracoccidioides lutzii which can exist as a
mycelia stage and yeast [58]. The mycelia form is found in
nature at temperatures between 18 and 25 °C and produces
spores or yeast-like conidia which may cause infections.
Spores inhaled by susceptible hosts are converted into yeast
in the tissues. By inhalation, spores target the lungs and later
on reach any systemic structure through the lymphatic or
blood stream, especially affecting skin, mucus membranes,
lymphatic tissue, and adrenal glands [59, 60]. Traumatic inoc-
ulation, in which the fungus settles on the skin mucosa, can
also occur. In most individuals, the disease is self-limited and
asymptomatic because of appropriate cellular immune re-
sponses [61].
The distribution of this disease is heterogenous showing
high and low endemicity in different areas in accordance with
climate and the environmental condition in the region. In LA,
PCM is considered one of the most important systemic myco-
ses [36], with Brazil, Venezuela, and Argentina the countries
with the greatest number of cases. Over than 80 % of
Paracoccidioidomycosis cases worldwide are from Brazil
where PCM is the eighth leading cause of death from chronic
infectious and parasitic diseases with the highest mortality rate
among systemic mycoses with a mean annual mortality rate
from 1980 to 1995 was 1.45/million inhabitants [62]. Reports
of cases in nonendemic areas are related to people who had
lived or visited endemic areas before the beginning of signs
and symptoms of the disease [58].
The disease exhibits many clinical presentations, which
may be roughly classified into two forms: acute/subacute
and chronic. Diversity of clinical presentation has been attrib-
uted to the enhanced pathogenicity of some P. brasiliensis
strains and particularly to host factors that modulate the im-
mune response against the fungus [63, 64].
This infection is more commonly acquired between the
first and second decades of life. Progression to the systemic
form in this period of the life is rare, between the third and fifth
decades of life, the disease is activated, causing the chronic
form of PCM [65]. Children and young adults most frequently
present with acute/subacute form of the disease (juvenile
type), which is a more widespread disease, involving the
lymphohematopoietic system (mainly liver) [66, 67]. Older
patients generally have a chronic form of the disease (adult
type), which affects primarily the lungs and upper airway [60].
Another factor that is important to note is the decrease of the
disease in females as they get older. In the prepuberal age,
PCM has been known to occur in similar proportions in boys
and girls, with a gender ratio of 1.7:1.0. After menarche, wom-
en become less susceptible to PCM due to the presence of
estrogens, which slowly inhibits the transformation of fila-
mentous phase, the infective, pathogenic yeast phase. In this
way, the chronic form is much more prevalent in men, with a
gender ratio of 15:1 [68, 69].
In our review, we found eight articles of PCM,mainly from
Brazil (seven) [30–34, 36, 37] and one from Argentina [35].
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From these, four were prospective studies [32–34, 37], one
retrospective [31], two case series [30, 35], and one descrip-
tive [36] (Appendix 2). The described prevalence of this dis-
ease from 0 to 29 years ranged from 2.3 to 35.3 %. Three
variables were related to a worse prognosis: age between 11
and 29 years, malnutrition, and hepatic involvement [33, 37].
Major clinical manifestations were generalized lymphadenop-
athy (95.1 %), weight loss (82.9 %), fever (78 %), asthenia
(63.4 %), splenomegaly (58.5 %), pallor (56.1 %), and in-
creased abdominal circunference; 40.1 % had liver involve-
ment with hepatomegaly detected by physical examination in
68.3 % of them [33]. Anemia, leukocytosis, eosinophilia, hy-
poalbuminemia, hypergamma globulinemia, and increased
erythrocyte sedimentation rate (ESR) were the most frequent
laboratory findings [33, 37].
The definitive diagnosis was made by histopathological
findings in most cases, followed by culture [33, 35]. Two
studies evaluated the intradermal reaction (gp43) and
showed a poor sensitivity; the exam was positive in 35.4
to 42.7 % of patients between 0 to 29 years of age. None
had clinical manifestations [32, 37].
The treatment of PCM includes supportive care and specif-
ic antifungals. P. brasiliensis is susceptible to the majority of
antifungals: amphotericin B, azoles: fluconazole,
i t r a conazo le ; ke toconazo l e , vo r i conazo le , and
sulfametoxazole/trimethoprim (TMT/SMX) [61].
Limited data exists comparing the different therapeutic ap-
proaches. Itraconazole is recommended for the mild forms due
the short time required to control the disease. Patients with se-
vere disease or intolerance to azoles must receive amphotericin
B or TMT/SMX intravenously as inpatient. TMT/SMXwas the
main drug used in children younger than 10 years old due to the
simple administration and tolerance [60].
Voriconazole can be recommended for patients with central
nervous system (CNS) involvement due to its effectiveness
[60].
In a clinical and laboratory study on pediatric patients with
and without hepatic involvement, trimethoprim–sulfamethox-
azole was the main drug used (26/41). An association with
amphotericin B, ketoconazole, or itraconazole was necessary
in 13/41 cases. The remaining patients (n=2/41) received a
single drug treatment with amphotericin B [33]. Another pe-
diatric series from Argentina used amphotericin B as first
choice (3/4) because of severity of the disease followed by
itraconazole to complete treatment. All patients survived
[35]. The duration of treatment is around 12 months and de-
pends on clinical and serological response [60]. Recommen-
da t ion fo r an t i funga l the rapy in ch i ld ren wi th
paracoccidiodomicosis is described in Table 3.
Cryptococcosis
Cryptococcosis is a systemic fungal disease associated with
high lethality. It is caused by Cryptococcus spp. which is an
encapsulated fungus that was considered an unusual pathogen
before 1955 and became a frequent opportunistic microorgan-
ism worldwide, as the population of immunocompromised
people increased [70]. Two species of Cryptococcus are the
most relevant to human health: Cryptococcus neoformans and
Cryptococcus gattii. The first has worldwide distribution and
is related to pigeon droppings, being more frequent in patients
with HIV/AIDS; by contrast, C. gattii is mainly distributed in
trees as Eucalyptus camaldulensi of tropical and subtropical
regions [71].
After the inhalation of viable airborne spores of these
yeasts directly from the environment, Cryptococcus spp. in-
vades the lung tissue and then a hematogenous dissemination
occurs, with a predisposition for the CNS [72]. However, there
are observations suggesting that infections by Cryptococcus
spp. can be asymptomatic and frequent in the early years of
life [73]. The disease may occur in immunocompetent
Table 3 Recommendations for management on paracoccidiodomicosis in pediatric patients adapted from Shikanai-Yasuda MA, 2006
Clinical Presentation Drug Dosage Duration
Mild and moderate
form—outpatients
First line Trimethoprim/sulfametoxazole Trimethoprin, 8 to 10mg/kg
and sulfametoxazole, 40
to 50mg/kg (PO) 12/12h
12months on mild
forms and 12 to 24 months
on moderate forms
Alternative Itraconazole Weighing <30kg and >
5years old
5 to 10mg/kg/day (PO)
6 to 9 months on mild
forms and 12 to 18 months
on moderate forms
Severe forms (disseminated
disease, CNS accomitiment,
respiratory failure, jaundice,
hemodynamic instability)—
inpatient
First line Trimethoprim/
sulfametoxazole
Trimethoprin, 8 to
10mg/kg and
sulfametoxazole,
40 to 50mg/kg, IV, BID/QD
Change for oral drug when it will be
possible
Alternative Amphotericin B 1mg/kg/day (IV)
Source: [60]
IV intravenously, PO orally
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individuals but is more frequent in immunocompromised pa-
tients mainly with HIV/AIDS who had impairment of cellular
immunity [71]. The mean annual incidence of cryptococcosis
in the general population in Colombia was 2.4 cases per 106
people between 1995 and 2010; in the population with human
immunodeficiency virus (HIV), the incidence ranged between
3 and 3.3 cases per 103 people. [39].
Global literature has described fewer cases in children than
adults [74], including those occurring in immunocompro-
mised patients. The prevalence of Cryptococcus spp. in chil-
dren with AIDS is estimated at 1 % and in adults about 6–8 %
[75]. The low frequency of cryptococcosis in children cannot
be explained by lack of exposure to the disease; in fact, one
study shows that the majority of children older than 2 years of
age have serological evidence of infection by C. neoformans
[73].
The clinical diagnosis of cryptococcemia is difficult as clin-
ical signs vary greatly due to infection in different organs [76].
Previous s tudies have shown that pat ients wi th
cryptococcemia have a high fever; then, fever with tremors
and chills in immunocompromised patients may be a warning
sign for suspecting cryptococcemia [77]. Meningitis and me-
ningoencephalitis are the most common clinical manifesta-
tions [78].
Usually, cryptococcosis diagnosis is made by mycological
examination of cerebrospinal fluid (CSF), tissue biopsy, spu-
tum, or other body fluids [79]. Approximately 80 % of AIDS
patients and 50 % of non-AIDS have fungus observed in di-
rect examination [70]. Cryptococcus spp. isolation from the
bloodstream is not rare, but few clinical/epidemiological stud-
ies have examined its role and the underlying etiological
agents. Previous studies reported blood culture as an impor-
tant diagnostic method for cryptococcosis in AIDS patients
[76, 80]. The ideal treatment is amphotericin B associated
with 5-fluorocytosin. It is necessary to control CSF samples
to certify the eradication of Cryptococcus spp. [81, 82]. A
sterile culture within 2 weeks of starting treatment confirms
the fungicidal action of drugs, and this is associated with ther-
apeutic success [83].
We evaluated two articles on cryptococcosis, one in Co-
lombia, descriptive, with a prevalence of 2.6 % in patients
under 16 years old [39] and the other in Uruguay, series of
cases, with patients in the range of 7–13 years [38] (Appendix
3). Only the descriptive study cited risk factors, with HIV
infection at the top (24.4 %), followed by 7.3 % of autoim-
mune diseases, steroid use, and hematological disease, and
2.3 % of kidney disease, solid tumor, and prematurity [39].
The most frequent clinical manifestations were headache
(78.1 %), fever (68.8 %), nausea and vomiting (65.6 %), con-
fusion (50 %), and meningeal signs (37.5 %); the most fre-
quent clinical presentations were meningitis, followed by dis-
seminated cryptococcosis [38, 39]. Direct examination was
the most used test for diagnosis, and capsular antigen detec-
tion was positive in all the cases that it was done, in serum and
in CSF. Culture was positive in 89.5 %, with C. neoformans
the most found (94.1 %) [38, 39]. The drug of choice was
amphotericin B (93.5 %), with fluconazole as maintenance
treatment [38, 39]. Recommendation for antifungal therapy
in children with cryptococcosis is described in Table 4.
Mold infections
Mold infections must be cited because of their importance in
immunocompromised patients. In this population, fungi are
responsible for most deaths from infections. The overall risk
of death in patients with mold infections can reach 30–70 %
[84]. Early diagnosis of invasive mold infections and prompt
implementation of aggressive antifungal treatment have prov-
en to be critical for patient survival. A major advancement in
Table 4 Recommendations for
management on cryptococosis in
pediatric patients adapted from
Perfect J, 2010
Clinical presentation Management
Induction and consolidation
therapy for CNS and
disseminated disease
d-AmB (1 mg/kg/day IV) plus flucytosine
(100 mg/kg/day orally in four divided doses)
for 2 weeks
Non-HIV-infected, nontransplant population, followed
by therapy with fluconazole (10–12 mg/kg per day orally)
for 8 weeks
For d-AmB intolerant patients, either L-AmB (5 mg/kg/day) or ABLC
(5 mg/kg/day)
Maintenance therapy is fluconazole (6 mg/kg/day orally)
Discontinuation of maintenance therapy in children receiving
HAART is poorly studied and must be individualized
Cryptococcal pneumonia Fluconazole (6–12 mg/kg/day orally) for 6–12 months
Source: [82]
d-AmB deoxicholate amphotericin B, L-AmB liposomal amphotericin B
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the approach for IFD in immunocompromised patients has
been the international consensus definition for IFD published
by the European Organization for Research and Treatment of
Cancer Classification (EORTC), together with the acceptance
of nonculture diagnostic techniques such as galactomannan
(GM) and the accessibility to more safe and efficient antifun-
gal therapies [85].
There are two prospective epidemiological studies pub-
lished in children in LA from Chile and from Brazil in 2013.
These studies evaluated the rate of IFD in children with cancer
(Chile) and in children and adults with acute myeloide leuke-
mia (AML) or myelodysplasia (MD) and underwent HSCT
(Brazil). In the first, the authors aimed to identify risk factors
for IFD in children with cancer, fever, and neutropenia in a
prospective, multicenter study. A diagnosis of proven, proba-
ble, and possible IFD was made after episode resolution based
on EORTC definitions. IFD was diagnosed in 35/604 febrile
neutropenic episodes evaluated (5.8 %), of which 7 (1.2 %)
were proven, 10 (1.6%) probable, and 18 (3.0%) possible; the
authors did not mention any antifungal prophylaxis in the
study. Most frequent mycosis in this population was candidi-
asis, followed by mold infections: invasive aspergillosis (IA)
and zygomycoses [45]. In the second study, the authors ob-
served a higher incidence of fusariosis in allogeneic HCT
cohort (5.2%) followed by IA and candidiasis. In study which
includes mainly adult population more than 70%were receiv-
ing antifungal prophylaxis with fluconazole [42].
Aspergillus spp. are ubiquitous fungi consistently document-
ed as some of the most prevalent airborne molds. Conidia of
Aspergillus species are often found in fireproofing or building
material and are dispersed by ventilation systems into indoor
air, including air within hospitals [44]. Infection is usually ini-
tiated by inhalation of airborne conidia and can cause a spec-
trum of clinical syndromes in the lung like IA, the most com-
mon in immunocompromissed patient particularly those with
prolonged and severe neutropenia due to cancer chemotherapy,
high-dose corticosteroids, or broad-spectrum antibiotics [86].
Some aspects of IA care appear to be the same for adults
and children, but there are important basic epidemiologic,
pathophysiologic, and treatment differences in IA in children
and adults. Unfortunately, only a few small studies of asper-
gillosis in children have been reported in literature [84,
86–91], none performed in LA. As shown by adult studies,
pulmonary IA is the clinical site most commonly identified
[84, 86]. The cutaneous presentation of aspergillosis appears
to be more common in children, from 13.7 % (19/139 pa-
tients) in a study published by Burgos in 2008 to 20 % (13/
66 patients) in St Jude review and 41 % (16/39 patients) in
Toronto study [84, 86, 87].
Early diagnosis is important to patient outcome, and the
clinician should have a high index of suspicion, especially in
patients with underlying malignancies who are neutropenic
with a prolonged fever despite systemic antimicrobial therapy.
Numerous diagnostic approaches should be utilized. Comput-
ed tomography (CT) chest is more sensitive and specific than
traditional chest radiographs in neutropenic patients and is
considered the best method of diagnosis for invasive pulmo-
nary aspergillosis. Nevertheless, it is important to note that the
incidence of classic radiological findings is lower in pediatric
patients than in adults; central cavitation of small nodules was
not so frequent in pediatric series [84]. Other tools like
galactomanan index (GMI) are useful for early diagnosis
and became positive before the images. The specificity of
the test may be lower in pediatric than adult patients [92]
and further validation of the GMI for the early diagnosis of
IA in high-risk pediatric patients is warranted. The recom-
mend treatment by IDSA is voriconazole (evidence AI) as
the same for adult [93]. Recommendation for antifungal ther-
apy in children with aspergillosis is described in Table 5.
Fusarium is a genus of widely distributed saprophytic
molds capable of causing disease in plants, animals, and
humans [94]. Invasive fusariosis is uncommon and predomi-
nately affects immunocompromised hosts, particularly those
with underlying hematological malignancy, neutropenia, and
Table 5 Recommendations for
management on invasive
aspergillosis in pediatric patients
adapted from Groll AH, 2014
Drug Dosage Duration
First line Voriconazole (AI) Children aged 2–12 or 12–14 years old and
weighing <50 kg: IV: (day 1): 8 mg/kg
twice daily and after 9 mg/kg twice daily
or PO: 9 mg/kg twice daily
Children aged ≥ 14years old or 12–14 years old
weighing ≥ 50 kg: IV: (day 1): 4 mg/kg
twice daily and after 6 mg/kg twice daily
or PO: 200 mg twice daily orally plus TDM
6 to 12 weeks
L-AmB (B-I) 3 mg/kg/day (IV)—once a day
Lipidic complex AmB (B-II) 5 mg/day (IV) once a day
Source: [93]
IV intravenously, PO orally, TDM therapeutic drug monitoring
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glucocorticoid exposure [95]. Although fusariosis is frequent
in Brazil and associated with a very high mortality rate, to our
knowledge, the literature in pediatric patients is scarce and
there is no other data from children in LA.
Conclusions
IFD are important causes of morbidity and mortality. The
knowledge of the incidence and prevalence in some regions is
very important as geographic differences can interfere in the
epidemiology of the species. Limited data in pediatric setting
is available in South America. Candida albicans remains as the
most frequent species of yeast isolated from bloodstream infec-
tions, but over the years, the numbers of candidemias caused by
non-albicans species has been increasing. C. parapsilosis is
more prevalent in younger children. PCM is an important my-
cose especially in Brazil with high rate of mortality and must be
considered in endemic areas. Cryptococcis occurred in associ-
ation with HIV infection, and the CNS clinical presentation is
the most common. Other mold infection like Aspergillus spp.,
Fusarium spp., and zygomycosis must be considered especially
in imunocompromised patients. More clinical studies must be
done in pediatrics regarding to epidemiology, risk factors, diag-
nosis, prevention, therapy, and prognosis.
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